cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ikena Oncology Inc
5 own
2 watching
Current Price
$5.97
$-0.22
(-3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
216.46M
52-Week High
52-Week High
7.64
52-Week Low
52-Week Low
1.94
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization216.46M
icon52-Week High7.64
icon52-Week Low1.94
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Ikena Oncology Inc do?
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More
How much money does Ikena Oncology Inc make?
News & Events about Ikena Oncology Inc.
Globe Newswire
1month ago
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930s differentiated paralog selectivity and robust repressor activity in complex with VGLL4 are key characteristics for potential tumor impact and increased therapeutic index Non...
Globe Newswire
2 months ago
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Companys ...
Ticker Report
5 months ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit ...
Zolmax
5 months ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit Suisse Group reduced ...
Globe Newswire
6 months ago
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway extended into 2025 BOSTON, ...
Frequently Asked Questions
Frequently Asked Questions
What is Ikena Oncology Inc share price today?
plus_minus_icon
Can Indians buy Ikena Oncology Inc shares?
plus_minus_icon
How can I buy Ikena Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Ikena Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ikena Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Ikena Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Ikena Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ikena Oncology Inc?
plus_minus_icon
What percentage is Ikena Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ikena Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.97
$-0.22
(-3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00